FDA-cleared profile

FlightPlan for Embolization

GE Medical Systems SCS · CBCT · FDA-cleared (510(k))

Authorized purpose: Post-processes 3D X-ray angiography to help physicians visualize vasculature during embolization planning.

Clinical role
Post-processing software for the planning phase of embolization that segments vasculature on 3D X-ray angiography and selectively displays vessels from a user-determined point, as an adjunct for physicians; it is not used during therapy delivery.
Images and patients
CBCT · Vasculature throughout the body
Key limitation
Keep in mind: For planning only; injection points require independent confirmation before therapy, and the AI segmentation option was validated for adults only.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Post-processes 3D X-ray angiography to help physicians visualize vasculature during embolization planning.
  • Which images or clinical context are in scope?Modality: CBCT Anatomy or clinical context: Vasculature throughout the body Input: Contrast-injected 3D X-ray angiography or CBCT acquired during embolization planning.
  • Who uses it?Intended users: Physicians.
  • What does the software produce?Output: Segmented vasculature, selective proximal/distal vessel display, and user-defined data export for guidance.
  • What is its most important limitation?Key limitation: For planning only; injection points require independent confirmation before therapy, and the AI segmentation option was validated for adults only.

Clinical takeaway. Clinical role: Post-processes 3D X-ray angiography to help physicians visualize vasculature during embolization planning.

Evidence takeaway. Evidence from the reviewed source record: FDA reported 207 unique-patient contrast-injected CBCT scans, with vessel-extraction success of 93.7% and root-definition success of 95.2%; diagnostic sensitivity and specificity were not reported.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Post-processes 3D X-ray angiography to help physicians visualize vasculature during embolization planning.
  • Exact FDA submission
  • Checked 2026-09-15

Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.

Workflow role
Post-processing software for the planning phase of embolization that segments vasculature on 3D X-ray angiography and selectively displays vessels from a user-determined point, as an adjunct for physicians; it is not used during therapy delivery.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "FlightPlan for Embolization is a post processing software package that helps the analysis of 3D X-ray angiography images. Its output is intended to be used by physicians as an adjunct means to help visualize vasculature during the planning phase of embolization procedures." … "The output includes segmented vasculature, and selective display of proximal vessel and distal vessels from a reference point determined by the user.". Read from the exact FDA decision document on 2026-11-14.

Required input
Contrast-injected 3D X-ray angiography or CBCT acquired during embolization planning.
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA input scope.

Output and clinician action
Segmented vasculature, selective proximal/distal vessel display, and user-defined data export for guidance.
  • Exact FDA submission
  • Checked 2026-09-15

FDA device-description scope.

Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Physicians.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet user statement.

Limitations
For planning only; injection points require independent confirmation before therapy, and the AI segmentation option was validated for adults only.
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA limitation boundary.

Evidence summary
FDA reported 207 unique-patient contrast-injected CBCT scans, with vessel-extraction success of 93.7% and root-definition success of 95.2%; diagnostic sensitivity and specificity were not reported.
  • Exact FDA submission
  • Checked 2026-09-15

Algorithm success rates are not diagnostic performance metrics.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA reported 207 unique-patient contrast-injected CBCT scans, with vessel-extraction success of 93.7% and root-definition success of 95.2%; diagnostic sensitivity and specificity were not reported.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

Algorithm success rates are not diagnostic performance metrics.

Reported sensitivity
N/A- not diagnostic application
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
N/A- not diagnostic application
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Embo ASSIST AI regulatory performance study summary

  • DesignStand-alone performance and reader study (ACR AI Central category)
  • PopulationAdult
  • Scopeexact submission
  • Tested versionvxtl_17.0-4.24
  • IndependenceIndependence not established

K223490

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K223490. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Contrast-injected 3D X-ray angiography or CBCT acquired during embolization planning.

    Scope: Exact FDA submission. Exact FDA input scope.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-15 · FDA K223490: FlightPlan for Embolization

  2. Routing

    Source context, not route validation: The exact FDA package describes processing 3D X-ray angiography (CBCT) images acquired from GE HealthCare's interventional X-ray system, saving results with optional export to other applications such as GEHC's Vision Applications for 3D road-mapping, and compliance with the NEMA PS 3.1-3.20 DICOM standard. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "The software process 3D X-ray angiography images (CBCT) acquired from GE HealthCare's interventional X-ray system [K181403]" … "Save results and optionally export them to other applications such as GEHC’s Vision Applications [K092639] for 3D road-mapping.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA K223490: FlightPlan for Embolization

  3. AI processing

    Source context, not route validation: The exact FDA package describes software that operates on GE HealthCare's Advantage Workstation (AW) and AW Server platforms as an extension to the Volume Viewer application, and was verified on AW VolumeShare workstation and AW Server platforms. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "operates on GEHC’s Advantage Workstation (AW) [K110834] platform and AW Server (AWS) [K081985] platform, and is an extension to the GE HealthCare’s Volume Viewer application" … "The proposed FlightPlan for Embolization has been successfully verified on the AW VolumeShare workstation [K110834] and AW Server [K081985] platforms.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K223490: FlightPlan for Embolization

  4. Returned objects

    Source context, not route validation: Segmented vasculature, selective proximal/distal vessel display, and user-defined data export for guidance.

    Scope: Exact FDA submission. FDA device-description scope.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-15 · FDA K223490: FlightPlan for Embolization

  5. Viewer/worklist/report

    Unresolved route: Segmented vasculature, selective proximal/distal vessel display, and user-defined data export for guidance.

    Scope: Exact FDA submission. FDA device-description scope.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-15 · FDA K223490: FlightPlan for Embolization

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes software that operates on GE HealthCare's Advantage Workstation (AW) and AW Server platforms as an extension to the Volume Viewer application, and was verified on AW VolumeShare workstation and AW Server platforms. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "operates on GEHC’s Advantage Workstation (AW) [K110834] platform and AW Server (AWS) [K081985] platform, and is an extension to the GE HealthCare’s Volume Viewer application" … "The proposed FlightPlan for Embolization has been successfully verified on the AW VolumeShare workstation [K110834] and AW Server [K081985] platforms.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact FDA package describes processing 3D X-ray angiography (CBCT) images acquired from GE HealthCare's interventional X-ray system, saving results with optional export to other applications such as GEHC's Vision Applications for 3D road-mapping, and compliance with the NEMA PS 3.1-3.20 DICOM standard. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The software process 3D X-ray angiography images (CBCT) acquired from GE HealthCare's interventional X-ray system [K181403]" … "Save results and optionally export them to other applications such as GEHC’s Vision Applications [K092639] for 3D road-mapping.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for FlightPlan for Embolization; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K223490
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CBCT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

FDA 3D X-ray angiography/CBCT normalized to the controlled CBCT bucket.

Anatomy
Vasculature throughout the body
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet scope.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-03-21
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
26Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K223490 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K223490: FlightPlan for Embolization

    U.S. Food and Drug Administration - Published 2023-03-21 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary, deployment, integration

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Embo ASSIST AI model card (K223490)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K223490

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K223490 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K250755

DS Core Diagnosis

Dentsply Sirona Inc.

Authorized purpose: Displays and supports interpretation of digital/digitized dental media, including CBCT and other 2D/3D X-ray images; its Panoramic Curve Proposal generates a proposed dental-arch curve for patients aged 12 years and older with permanent dentition that a clinician can review and adjust.

Modality
CBCT
Anatomy
Dental/Maxillofacial
Decision
2025-08-12
FDA-cleared K243989

Second Opinion® 3D

Pearl, Inc.

Authorized purpose: Second Opinion 3D processes dental CBCT radiographs to identify and mark dentition, maxilla, mandible, inferior alveolar canal and mental foramen, maxillary sinus, nasal space, and airway for review by dental health professionals age 12 and older; it is a concurrent or second reader, not a sole diagnosis.

Modality
CBCT
Anatomy
Dental and craniomaxillofacial anatomy
Decision
2025-05-23
FDA-cleared K233925

Relu Creator

Relu BV

Authorized purpose: Relu Creator manages, transfers, displays, enhances, and analyzes dental and craniomaxillofacial image information and provides design input for dental solutions within the labeled workflow.

Modality
CBCT
Anatomy
Dental/Maxillofacial
Decision
2024-06-13
FDA-cleared K260785

DS Core CBCT Anatomy

Dentsply Sirona

Authorized purpose: DS Core CBCT Anatomy uses CBCT and digital-impression data to provide tooth and jaw segmentation, inferior-alveolar-nerve-canal segmentation, panoramic-curve support, and registration for dental professionals.

Modality
CBCT
Anatomy
Teeth; jaws; and the inferior alveolar nerve canal
Decision
2026-04-23

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history